The fact that one in five patients carried a loss-of-function variant in BRCA1, BRCA2, or another breast cancer gene with a highly heterogeneous mutational spectrum underscores the importance of utilizing next-generation sequencing-based testing to develop screening and risk-reducing strategies in Northeast Brazil. This evidence concerns the gene BRCA2 and breast carcinoma.